Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989516 | 0.84 | PTGS2 (0.47) | PTGS2PTGS1NR3C1PGRNR3C2 | |
| SCHEMBL10277467 | 0.83 | PTGS2 (0.49) | PTGS2PTGS1PTPRCPTPN1FEN1 | |
| SCHEMBL2352009 | 0.79 | PTGS2 (0.51) | PTGS2PTGS1ERN1 | |
| SCHEMBL4150829 | 0.79 | LMNA (0.43) | PTGS2PTGS1NR3C1PGRERN1 | |
| SCHEMBL1998315 | 0.78 | NR3C1 (0.49) | PTGS2PTGS1NR3C1PGRNR3C2 | |
| SCHEMBL1989562 | 0.77 | PTGS2 (0.45) | PTGS2PTGS1NR3C1PGRERN1 | |
| SCHEMBL10277289 | 0.76 | LMNA (0.43) | PTGS2PTGS1NR3C1PGRFEN1 | |
| SCHEMBL1989553 | 0.76 | HTR6 (0.51) | PTGS2PTGS1NR3C1PGRNR3C2 | |
| SCHEMBL10277468 | 0.74 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL1990346 | 0.69 | HTR6 (0.49) | PTGS2PTGS1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGS2 1220/4885PTGS1 1276/4885NR3C1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.